ALLO's logo.
Ticker Symbol: ALLO

Allogene Therapeutics Inc

$19.37 - 04-12-2024 4 p.m. ET

Exchange: NASDAQ Currency: USD Asset Type: Common Stock CIK:0001737287

Company Profile

allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le

Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Standard Industrial Classification Code (SIC code): 2836
Address: N/A
Website: allogene.com
CEO: N/A
Tags:
  • Health Technology
  • Biotechnology

Pricing

Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $3.00
Change: $0.02 ( 0.67%)
Days Range: $2.94 - $3.14
Beta: 1.36
52wk. High: $11.10
52wk. Low: $2.88
Ytd. Change -51.63%
50 Day Moving Average: $3.48
200 Day Moving Average: $4.69
Shares Outstanding: 167626365

Valuation

Market Cap: 50.3B
PE Ratio: -1.22
EPS (TTM): -2.45

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A